Pancreatic β- Cell dysfunction and risk of new-onset diabetes after kidney transplantation

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 1926-1932

  Zelle, Dorien M ^a   Corpeleijn, Eva ^a   Deinum, Jolijn ^a   Stolk, Ronald P ^a   Gans, Rijk O B ^a   Navis, Gerjan ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROINSULIN; RAPAMYCIN; TACROLIMUS;

ADULT; AGE; ARTICLE; BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GINGIVA HYPERTROPHY; GRAFT RECIPIENT; HUMAN; HYPERTRICHOSIS; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; DIABETES MELLITUS; FASTING; HUMANS; INSULIN-SECRETING CELLS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROINSULIN; PROSPECTIVE STUDIES;

EID: 84878664812     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1894     Document Type: Article

References (32)

1. Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant 2008;23:2033-2042
2. Chadban S. New-onset diabetes after transplantationdshould it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients. Nephrol Dial Transplant 2008;23:1816-1818
3. Kasiske BL, Snyder JJ, Gilbertson D,Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185
4. Bee YM, Tan HC, Tay TL, Kee TY, Goh SY, Kek PC. Incidence and risk factors for development of new-onset diabetes after kidney transplantation. Ann Acad Med Singapore 2011;40:160-167
5. Pfützner A, Pfützner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther 2004;6:405-412
6. Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis andmanagement strategies.Clin J AmSocNephrol 2008;3(Suppl 2):S38-S48
7. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91:334-341
8. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-821
9. Pfützner A, Pfützner AH, Kann PH, et al. Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin. Clin Lab 2005;51:243-249
10. Zelle DM, Corpeleijn E, Van Ree RM, et al. Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients. Am J Transplant 2010;10:106-114
11. Oterdoom LH, Van Ree RM, De Vries AP, et al. Urinary creatinine excretion reflectingmuscle mass is a predictor of mortality and graft loss in renal transplant recipients. Transplantation 2008;86:391-398
12. Oterdoom LH, De Vries AP, Van Son WJ, et al. Validation of insulin resistance indexes in a stable renal transplant population. Diabetes Care 2005;28:2424-2429
13. National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blooz Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
14. Davidson J, Wilkinson A, Dantal J, et al; International Expert Panel. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75(Suppl): SS3-SS24
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5-S20
16. Balkau B, Lange C, Fezeu L, et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2008; 31:2056-2061
17. Harrell FE. Regression modeling strategies: with applications to linear models, logisticregression, and survival analysis. 2001. New York, Springer.
18. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46:3-19
19. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 2002;51(Suppl 1):S212-S220
20. Oterdoom LH, De Vries AP, Gansevoort RT, et al. Determinants of insulin resistance in renal transplant recipients. Transplantation 2007;83:29-35
21. Ajabnoor MA, El-Naggar MM, Elayat AA, Abdulrafee A. Functional and morphological study of cultured pancreatic islets treated with cyclosporine. Life Sci 2007; 80:345-355
22. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98:2786-2793
23. Øzbay LA, Smidt K, Mortensen DM, Carstens J, J ørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.Br J Pharmacol 2011;162: 136-146
24. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-αnalysis and meta-regression of randomised trial data. BMJ 2005;331:810
25. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258
26. Galloway JA,Hooper SA, SpradlinCT, et al. Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 1992;15:666-692
27. Pfützner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27:682-687
28. Sharif A, Ravindran V, Moore RH, et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. Transplantation 2010; 89:327-333
29. Rodrigo E, Santos L, Piñera C, et al. Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. Diabetes Care 2012;35:471-473
30. Chakkera HA, Weil EJ, Swanson CM, et al. Pretransplant risk score for newonset diabetes after kidney transplantation. Diabetes Care 2011;34:2141-2145
31. Hecking M, Haidinger M, Döller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012;23:739-749
32. Sharif A, Moore R, Baboolal K. Influence of lifestylemodification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008;85:353-358